Taysha Gene Therapies (Nasdaq:TSHA) - Stock Price, News & Analysis

TSHA Stock Overview

TSHA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Se prevé un crecimiento anual de los ingresos de 31.55%

Los analistas coinciden en que el precio de las acciones subirá un 144.9%

Risk Analysis

Los accionistas han sido diluidos sustancialmente en el último año

Cotización muy volátil en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Taysha Gene Therapies, Inc. Competitors

Applied Therapeutics

NasdaqGM:APLT

US$612.0m

Verve Therapeutics

NasdaqGS:VERV

US$712.4m

Entrada Therapeutics

NasdaqGM:TRDA

US$446.5m

Mersana Therapeutics

NasdaqGS:MRSN

US$519.2m

Price History & Performance

Summary of all time highs, changes and price drops for Taysha Gene Therapies
Historical stock prices
Current Share Price	US$2.68
52 Week High	US$3.89
52 Week Low	US$0.50
Beta	0.26
1 Month Change	6.35%
3 Month Change	39.58%
1 Year Change	303.01%
3 Year Change	-89.28%
5 Year Change	n/a
Change since IPO	-88.86%

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20

Taysha: Produces Solid Data But Has Abandoned Programs

Feb 06

Recent updates

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push

Jan 13

Taysha teams up with AllStripes to advance gene therapy in rare disorder

Jan 04

What Kind Of Shareholders Hold The Majority In Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares?

Dec 24

Taysha on go with early-stage study with its gene therapy in inherited lysosomal storage disorder

Dec 21

Shareholder Returns

	TSHA	US Biotechs	US Market
7D	-5.6%	-4.1%	-0.7%
1Y	303.0%	4.0%	25.9%

Rentabilidad frente al sector: TSHA superó al sector US Biotechs , que obtuvo un rendimiento del 5.8% el año pasado.

Rentabilidad vs. Mercado: TSHA superó al mercado US, que obtuvo un rendimiento del 22.3% el año pasado.

Price Volatility

Is TSHA's price volatile compared to industry and market?
TSHA volatility
TSHA Average Weekly Movement	17.6%
Biotechs Industry Average Movement	11.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: TSHAha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: TSHAha disminuido de 30% a 14% en el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2019	52	Sean Nolan	https://www.tayshagtx.com

Taysha Gene Therapies, Inc. es una empresa de terapia génica centrada en el desarrollo y la comercialización de terapias génicas basadas en virus adenoasociados para el tratamiento de enfermedades monogénicas del sistema nervioso central. Desarrolla principalmente TSHA-120 para el tratamiento de la neuropatía axonal gigante; TSHA-102 para el tratamiento del síndrome de Rett; TSHA-121 para el tratamiento de la enfermedad CLN7; TSHA-118 para el tratamiento de la enfermedad CLN1; TSHA-105 para el tratamiento de la deficiencia de SLC13A5; TSHA-113 para el tratamiento de las tauopatías; TSHA-106 para el tratamiento del síndrome de Angelman; TSHA-114 para el tratamiento del síndrome X frágil; y TSHA-101 para el tratamiento de la gangliosidosis GM2. Taysha Gene Therapies, Inc. mantiene una asociación estratégica con el Centro Médico Southwestern de la Universidad de Texas.

Taysha Gene Therapies, Inc. Fundamentals Summary

How do Taysha Gene Therapies's earnings and revenue compare to its market cap?
TSHA fundamental statistics
Market cap	US$501.21m
Earnings (TTM)	-US$111.57m
Revenue (TTM)	US$15.45m

32.4x

P/S Ratio

-4.5x

P/E Ratio

Is TSHA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TSHA income statement (TTM)
Revenue	US$15.45m
Cost of Revenue	US$0
Gross Profit	US$15.45m
Other Expenses	US$127.02m
Earnings	-US$111.57m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.60
Gross Margin	100.00%
Net Profit Margin	-722.06%
Debt/Equity Ratio	54.1%

How did TSHA perform over the long term?

See historical performance and comparison

TSHA Stock Overview

Rewards

Risk Analysis

Taysha Gene Therapies, Inc. Competitors

NasdaqGM:APLT

US$612.0m

NasdaqGS:VERV

US$712.4m

NasdaqGM:TRDA

US$446.5m

NasdaqGS:MRSN

US$519.2m

Price History & Performance

Recent News & Updates

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Recent updates

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 2000 Growth Index

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

Price target decreased to US$39.07

Taysha Gene Therapies Gets A 'Thumbs Up'

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease At 18th Annual WORLDSymposium

Independent Director recently bought US$80k worth of stock

Taysha Gene Therapies, Inc. Reports Positive Clinical Efficacy and Safety Data for the High Dose Cohort of 3.5X10 Total Vg

Taysha Gene Therapies, Inc. Announces Positive Initial Biomarker Data for TSHA-101

High number of new and inexperienced directors

Taysha Gene Therapies, Inc Announces Plans to Provide Clinical Data Updates

Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design

Taysha Gene Therapies Announces Initiation of Clinical Development of Tsha-118 for the Treatment of Cln1 Disease